APO Research
Talk to an analyst

APO RESEARCH · REPORT

Targeted SSTR Radionuclide Drug Conjugates

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Targeted SSTR Radionuclide Drug Conjugates Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

28 December 2025187 pages

Choose your research edition.

Industry ResearchTargeted SSTR Radionuclide Drug Conjugates Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Targeted SSTR Radionuclide Drug Conjugates Industry Growth and Trends Forecast to 203299 pages · $3,450 USDMarket StructureGlobal Targeted SSTR Radionuclide Drug Conjugates Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032187 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Targeted SSTR Radionuclide Drug Conjugates Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Targeted SSTR Radionuclide Drug Conjugates Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Targeted SSTR Radionuclide Drug Conjugates market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Targeted SSTR Radionuclide Drug Conjugates is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Targeted SSTR Radionuclide Drug Conjugates is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Targeted SSTR Radionuclide Drug Conjugates is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Targeted SSTR Radionuclide Drug Conjugates is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Targeted SSTR Radionuclide Drug Conjugates include Curium Pharma, ITM Radiopharma, RadioMedix, Novartis and Grand Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Targeted SSTR Radionuclide Drug Conjugates market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Targeted SSTR Radionuclide Drug Conjugates and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Targeted SSTR Radionuclide Drug Conjugates sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Targeted SSTR Radionuclide Drug Conjugates market size, projected growth trends, production technologies, key applications, and end-use industries.

Targeted SSTR Radionuclide Drug Conjugates Segment by Company

Curium Pharma

ITM Radiopharma

RadioMedix

Novartis

Grand Pharmaceutical

Targeted SSTR Radionuclide Drug Conjugates Segment by Type

Diagnostic

Therapeutic

Targeted SSTR Radionuclide Drug Conjugates Segment by Application

Hospital

Specialist Clinic

Other

Targeted SSTR Radionuclide Drug Conjugates Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Targeted SSTR Radionuclide Drug Conjugates market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Targeted SSTR Radionuclide Drug Conjugates and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Targeted SSTR Radionuclide Drug Conjugates.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Targeted SSTR Radionuclide Drug Conjugates market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Targeted SSTR Radionuclide Drug Conjugates manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Targeted SSTR Radionuclide Drug Conjugates in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Targeted SSTR Radionuclide Drug Conjugates in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Targeted SSTR Radionuclide Drug Conjugates Industry Trends Table 2. Targeted SSTR Radionuclide Drug Conjugates Industry Drivers Table 3. Targeted SSTR Radionuclide Drug Conjugates Industry Opportunities and Challenges Table 4. Targeted SSTR Radionuclide Drug Conjugates Industry Restraints Table 5. Global Targeted SSTR Radionuclide Drug Conjugates Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Targeted SSTR Radionuclide Drug Conjugates Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Targeted SSTR Radionuclide Drug Conjugates Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Targeted SSTR Radionuclide Drug Conjugates Sales Market Share by Manufacturers Table 9. Global Targeted SSTR Radionuclide Drug Conjugates Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Targeted SSTR Radionuclide Drug Conjugates Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Targeted SSTR Radionuclide Drug Conjugates Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Targeted SSTR Radionuclide Drug Conjugates Manufacturers, Product Type & Application Table 13. Global Targeted SSTR Radionuclide Drug Conjugates Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Targeted SSTR Radionuclide Drug Conjugates by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Diagnostic Table 17. Major Manufacturers of Therapeutic Table 18. Global Targeted SSTR Radionuclide Drug Conjugates Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 19. Global Targeted SSTR Radionuclide Drug Conjugates Sales by Type (2021-2026) & (K Units) Table 20. Global Targeted SSTR Radionuclide Drug Conjugates Sales by Type (2027-2032) & (K Units) Table 21. Global Targeted SSTR Radionuclide Drug Conjugates Sales Market Share by Type (2021-2026) Table 22. Global Targeted SSTR Radionuclide Drug Conjugates Sales Market Share by Type (2027-2032) Table 23. Global Targeted SSTR Radionuclide Drug Conjugates Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global Targeted SSTR Radionuclide Drug Conjugates Revenue by Type (2021-2026) & (K Units) Table 25. Global Targeted SSTR Radionuclide Drug Conjugates Revenue by Type (2027-2032) & (K Units) Table 26. Global Targeted SSTR Radionuclide Drug Conjugates Revenue Market Share by Type (2021-2026) Table 27. Global Targeted SSTR Radionuclide Drug Conjugates Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Hospital Table 29. Major Manufacturers of Specialist Clinic Table 30. Major Manufacturers of Other Table 31. Global Targeted SSTR Radionuclide Drug Conjugates Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 32. Global Targeted SSTR Radionuclide Drug Conjugates Sales by Application (2021-2026) & (K Units) Table 33. Global Targeted SSTR Radionuclide Drug Conjugates Sales by Application (2027-2032) & (K Units) Table 34. Global Targeted SSTR Radionuclide Drug Conjugates Sales Market Share by Application (2021-2026) Table 35. Global Targeted SSTR Radionuclide Drug Conjugates Sales Market Share by Application (2027-2032) Table 36. Global Targeted SSTR Radionuclide Drug Conjugates Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 37. Global Targeted SSTR Radionuclide Drug Conjugates Revenue by Application (2021-2026) & (K Units) Table 38. Global Targeted SSTR Radionuclide Drug Conjugates Revenue by Application (2027-2032) & (K Units) Table 39. Global Targeted SSTR Radionuclide Drug Conjugates Revenue Market Share by Application (2021-2026) Table 40. Global Targeted SSTR Radionuclide Drug Conjugates Revenue Market Share by Application (2027-2032) Table 41. Global Targeted SSTR Radionuclide Drug Conjugates Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 42. Global Targeted SSTR Radionuclide Drug Conjugates Sales by Region (2021-2026) & (K Units) Table 43. Global Targeted SSTR Radionuclide Drug Conjugates Sales Market Share by Region (2021-2026) Table 44. Global Targeted SSTR Radionuclide Drug Conjugates Sales Forecasted by Region (2027-2032) & (K Units) Table 45. Global Targeted SSTR Radionuclide Drug Conjugates Sales Forecasted Market Share by Region (2027-2032) Table 46. North America Targeted SSTR Radionuclide Drug Conjugates Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 47. North America Targeted SSTR Radionuclide Drug Conjugates Sales by Country (2021-2026) & (K Units) Table 48. North America Targeted SSTR Radionuclide Drug Conjugates Sales by Country (2027-2032) & (K Units) Table 49. Europe Targeted SSTR Radionuclide Drug Conjugates Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 50. Europe Targeted SSTR Radionuclide Drug Conjugates Sales by Country (2021-2026) & (K Units) Table 51. Europe Targeted SSTR Radionuclide Drug Conjugates Sales by Country (2027-2032) & (K Units) Table 52. Asia Pacific Targeted SSTR Radionuclide Drug Conjugates Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 53. Asia Pacific Targeted SSTR Radionuclide Drug Conjugates Sales by Country (2021-2026) & (K Units) Table 54. Asia Pacific Targeted SSTR Radionuclide Drug Conjugates Sales by Country (2027-2032) & (K Units) Table 55. South America, Middle East and Africa Targeted SSTR Radionuclide Drug Conjugates Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. South America, Middle East and Africa Targeted SSTR Radionuclide Drug Conjugates Sales by Country (2021-2026) & (K Units) Table 57. South America, Middle East and Africa Targeted SSTR Radionuclide Drug Conjugates Sales by Country (2027-2032) & (K Units) Table 58. Global Targeted SSTR Radionuclide Drug Conjugates Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Targeted SSTR Radionuclide Drug Conjugates Revenue by Region (2021-2026) & (US$ Million) Table 60. Global Targeted SSTR Radionuclide Drug Conjugates Revenue by Region (2027-2032) & (US$ Million) Table 61. Global Targeted SSTR Radionuclide Drug Conjugates Revenue Market Share by Region (2021-2026) Table 62. Global Targeted SSTR Radionuclide Drug Conjugates Revenue Market Share by Region (2027-2032) Table 63. Curium Pharma Company Information Table 64. Curium Pharma Business Overview Table 65. Curium Pharma Targeted SSTR Radionuclide Drug Conjugates Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Curium Pharma Targeted SSTR Radionuclide Drug Conjugates Product Portfolio Table 67. Curium Pharma Recent Development Table 68. ITM Radiopharma Company Information Table 69. ITM Radiopharma Business Overview Table 70. ITM Radiopharma Targeted SSTR Radionuclide Drug Conjugates Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. ITM Radiopharma Targeted SSTR Radionuclide Drug Conjugates Product Portfolio Table 72. ITM Radiopharma Recent Development Table 73. RadioMedix Company Information Table 74. RadioMedix Business Overview Table 75. RadioMedix Targeted SSTR Radionuclide Drug Conjugates Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. RadioMedix Targeted SSTR Radionuclide Drug Conjugates Product Portfolio Table 77. RadioMedix Recent Development Table 78. Novartis Company Information Table 79. Novartis Business Overview Table 80. Novartis Targeted SSTR Radionuclide Drug Conjugates Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Novartis Targeted SSTR Radionuclide Drug Conjugates Product Portfolio Table 82. Novartis Recent Development Table 83. Grand Pharmaceutical Company Information Table 84. Grand Pharmaceutical Business Overview Table 85. Grand Pharmaceutical Targeted SSTR Radionuclide Drug Conjugates Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Grand Pharmaceutical Targeted SSTR Radionuclide Drug Conjugates Product Portfolio Table 87. Grand Pharmaceutical Recent Development Table 88. Key Raw Materials Table 89. Raw Materials Key Suppliers Table 90. Targeted SSTR Radionuclide Drug Conjugates Distributors List Table 91. Targeted SSTR Radionuclide Drug Conjugates Customers List Table 92. Research Programs/Design for This Report Table 93. Authors List of This Report Table 94. Secondary Sources Table 95. Primary Sources List of Figures Figure 1. Targeted SSTR Radionuclide Drug Conjugates Product Image Figure 2. Global Targeted SSTR Radionuclide Drug Conjugates Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Targeted SSTR Radionuclide Drug Conjugates Market Size (2021-2032) & (US$ Million) Figure 4. Global Targeted SSTR Radionuclide Drug Conjugates Sales (2021-2032) & (K Units) Figure 5. Global Targeted SSTR Radionuclide Drug Conjugates Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Targeted SSTR Radionuclide Drug Conjugates Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Diagnostic Image Figure 9. Therapeutic Image Figure 10. Global Targeted SSTR Radionuclide Drug Conjugates Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 11. Global Targeted SSTR Radionuclide Drug Conjugates Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Targeted SSTR Radionuclide Drug Conjugates Sales Market Share by Type (2021-2032) Figure 13. Global Targeted SSTR Radionuclide Drug Conjugates Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Targeted SSTR Radionuclide Drug Conjugates Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Targeted SSTR Radionuclide Drug Conjugates Revenue Market Share by Type (2021-2032) Figure 16. Hospital Image Figure 17. Specialist Clinic Image Figure 18. Other Image Figure 19. Global Targeted SSTR Radionuclide Drug Conjugates Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 20. Global Targeted SSTR Radionuclide Drug Conjugates Sales Market Share 2021 VS 2025 VS 2032 Figure 21. Global Targeted SSTR Radionuclide Drug Conjugates Sales Market Share by Application (2021-2032) Figure 22. Global Targeted SSTR Radionuclide Drug Conjugates Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Targeted SSTR Radionuclide Drug Conjugates Revenue Market Share 2021 VS 2025 VS 2032 Figure 24. Global Targeted SSTR Radionuclide Drug Conjugates Revenue Market Share by Application (2021-2032) Figure 25. North America Targeted SSTR Radionuclide Drug Conjugates Sales and Growth Rate (2021-2032) & (K Units) Figure 26. North America Targeted SSTR Radionuclide Drug Conjugates Sales Market Share by Country (2021-2032) Figure 27. U.S. Targeted SSTR Radionuclide Drug Conjugates Sales and Growth Rate (2021-2032) & (K Units) Figure 28. Canada Targeted SSTR Radionuclide Drug Conjugates Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Mexico Targeted SSTR Radionuclide Drug Conjugates Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Europe Targeted SSTR Radionuclide Drug Conjugates Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Europe Targeted SSTR Radionuclide Drug Conjugates Sales Market Share by Country (2021-2032) Figure 32. Germany Targeted SSTR Radionuclide Drug Conjugates Sales and Growth Rate (2021-2032) & (K Units) Figure 33. France Targeted SSTR Radionuclide Drug Conjugates Sales and Growth Rate (2021-2032) & (K Units) Figure 34. U.K. Targeted SSTR Radionuclide Drug Conjugates Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Italy Targeted SSTR Radionuclide Drug Conjugates Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Netherlands Targeted SSTR Radionuclide Drug Conjugates Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Asia Pacific Targeted SSTR Radionuclide Drug Conjugates Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Asia Pacific Targeted SSTR Radionuclide Drug Conjugates Sales Market Share by Country (2021-2032) Figure 39. China Targeted SSTR Radionuclide Drug Conjugates Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Japan Targeted SSTR Radionuclide Drug Conjugates Sales and Growth Rate (2021-2032) & (K Units) Figure 41. South Korea Targeted SSTR Radionuclide Drug Conjugates Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Southeast Asia Targeted SSTR Radionuclide Drug Conjugates Sales and Growth Rate (2021-2032) & (K Units) Figure 43. India Targeted SSTR Radionuclide Drug Conjugates Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Australia Targeted SSTR Radionuclide Drug Conjugates Sales and Growth Rate (2021-2032) & (K Units) Figure 45. South America, Middle East and Africa Targeted SSTR Radionuclide Drug Conjugates Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South America, Middle East and Africa Targeted SSTR Radionuclide Drug Conjugates Sales Market Share by Country (2021-2032) Figure 47. Brazil Targeted SSTR Radionuclide Drug Conjugates Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South Africa Targeted SSTR Radionuclide Drug Conjugates Sales and Growth Rate (2021-2032) & (K Units) Figure 49. Saudi Arabia Targeted SSTR Radionuclide Drug Conjugates Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Turkey Targeted SSTR Radionuclide Drug Conjugates Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Argentina Targeted SSTR Radionuclide Drug Conjugates Sales and Growth Rate (2021-2032) & (K Units) Figure 52. UAE Targeted SSTR Radionuclide Drug Conjugates Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Egypt Targeted SSTR Radionuclide Drug Conjugates Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Chile Targeted SSTR Radionuclide Drug Conjugates Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Global Targeted SSTR Radionuclide Drug Conjugates Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Global Targeted SSTR Radionuclide Drug Conjugates Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 57. North America Targeted SSTR Radionuclide Drug Conjugates Revenue (2021-2032) & (US$ Million) Figure 58. North America Targeted SSTR Radionuclide Drug Conjugates Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 59. Europe Targeted SSTR Radionuclide Drug Conjugates Revenue (2021-2032) & (US$ Million) Figure 60. Europe Targeted SSTR Radionuclide Drug Conjugates Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific Targeted SSTR Radionuclide Drug Conjugates Revenue (2021-2032) & (US$ Million) Figure 62. Asia-Pacific Targeted SSTR Radionuclide Drug Conjugates Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. South America, Middle East and Africa Targeted SSTR Radionuclide Drug Conjugates Revenue (2021-2032) & (US$ Million) Figure 64. South America, Middle East and Africa Targeted SSTR Radionuclide Drug Conjugates Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Targeted SSTR Radionuclide Drug Conjugates Value Chain Figure 66. Manufacturing Cost Structure Figure 67. Targeted SSTR Radionuclide Drug Conjugates Production Mode & Process Figure 68. Direct Comparison with Distribution Share Figure 69. Distributors Profiles Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Diagnostic
  • Therapeutic
Applications
  • Hospital
  • Specialist Clinic
  • Other
Companies covered
  • Curium Pharma
  • ITM Radiopharma
  • RadioMedix
  • Novartis
  • Grand Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Targeted SSTR Radionuclide Drug Conjugates Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Targeted SSTR Radionuclide Drug Conjugates Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Targeted SSTR Radionuclide Drug Conjugates Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Targeted SSTR Radionuclide Drug Conjugates Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Targeted SSTR Radionuclide Drug Conjugates Market Dynamics
  1. 2.1 Targeted SSTR Radionuclide Drug Conjugates Industry Trends
  2. 2.2 Targeted SSTR Radionuclide Drug Conjugates Industry Drivers
  3. 2.3 Targeted SSTR Radionuclide Drug Conjugates Industry Opportunities and Challenges
  4. 2.4 Targeted SSTR Radionuclide Drug Conjugates Industry Restraints
3 Targeted SSTR Radionuclide Drug Conjugates Market by Manufacturers
  1. 3.1 Global Targeted SSTR Radionuclide Drug Conjugates Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Targeted SSTR Radionuclide Drug Conjugates Sales by Manufacturers (2021-2026)
  3. 3.3 Global Targeted SSTR Radionuclide Drug Conjugates Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Targeted SSTR Radionuclide Drug Conjugates Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Targeted SSTR Radionuclide Drug Conjugates Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Targeted SSTR Radionuclide Drug Conjugates Manufacturers, Product Type & Application
  7. 3.7 Global Targeted SSTR Radionuclide Drug Conjugates Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Targeted SSTR Radionuclide Drug Conjugates Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Targeted SSTR Radionuclide Drug Conjugates Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Targeted SSTR Radionuclide Drug Conjugates Tier 1, Tier 2, and Tier 3
4 Targeted SSTR Radionuclide Drug Conjugates Market by Type
  1. 4.1 Targeted SSTR Radionuclide Drug Conjugates Type Introduction
  2. 4.1.1 Diagnostic
  3. 4.1.2 Therapeutic
  4. 4.2 Global Targeted SSTR Radionuclide Drug Conjugates Sales by Type
  5. 4.2.1 Global Targeted SSTR Radionuclide Drug Conjugates Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Targeted SSTR Radionuclide Drug Conjugates Sales by Type (2021-2032)
  7. 4.2.3 Global Targeted SSTR Radionuclide Drug Conjugates Sales Market Share by Type (2021-2032)
  8. 4.3 Global Targeted SSTR Radionuclide Drug Conjugates Revenue by Type
  9. 4.3.1 Global Targeted SSTR Radionuclide Drug Conjugates Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Targeted SSTR Radionuclide Drug Conjugates Revenue by Type (2021-2032)
  11. 4.3.3 Global Targeted SSTR Radionuclide Drug Conjugates Revenue Market Share by Type (2021-2032)
5 Targeted SSTR Radionuclide Drug Conjugates Market by Application
  1. 5.1 Targeted SSTR Radionuclide Drug Conjugates Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Specialist Clinic
  4. 5.1.3 Other
  5. 5.2 Global Targeted SSTR Radionuclide Drug Conjugates Sales by Application
  6. 5.2.1 Global Targeted SSTR Radionuclide Drug Conjugates Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Targeted SSTR Radionuclide Drug Conjugates Sales by Application (2021-2032)
  8. 5.2.3 Global Targeted SSTR Radionuclide Drug Conjugates Sales Market Share by Application (2021-2032)
  9. 5.3 Global Targeted SSTR Radionuclide Drug Conjugates Revenue by Application
  10. 5.3.1 Global Targeted SSTR Radionuclide Drug Conjugates Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Targeted SSTR Radionuclide Drug Conjugates Revenue by Application (2021-2032)
  12. 5.3.3 Global Targeted SSTR Radionuclide Drug Conjugates Revenue Market Share by Application (2021-2032)
6 Global Targeted SSTR Radionuclide Drug Conjugates Sales by Region
  1. 6.1 Global Targeted SSTR Radionuclide Drug Conjugates Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Targeted SSTR Radionuclide Drug Conjugates Sales by Region (2021-2032)
  3. 6.2.1 Global Targeted SSTR Radionuclide Drug Conjugates Sales by Region (2021-2026)
  4. 6.2.2 Global Targeted SSTR Radionuclide Drug Conjugates Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Targeted SSTR Radionuclide Drug Conjugates Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Targeted SSTR Radionuclide Drug Conjugates Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Targeted SSTR Radionuclide Drug Conjugates Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Targeted SSTR Radionuclide Drug Conjugates Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Targeted SSTR Radionuclide Drug Conjugates Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Targeted SSTR Radionuclide Drug Conjugates Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Targeted SSTR Radionuclide Drug Conjugates Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Targeted SSTR Radionuclide Drug Conjugates Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Targeted SSTR Radionuclide Drug Conjugates Revenue by Region
  1. 7.1 Global Targeted SSTR Radionuclide Drug Conjugates Revenue by Region
  2. 7.1.1 Global Targeted SSTR Radionuclide Drug Conjugates Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Targeted SSTR Radionuclide Drug Conjugates Revenue by Region (2021-2026)
  4. 7.1.3 Global Targeted SSTR Radionuclide Drug Conjugates Revenue by Region (2027-2032)
  5. 7.1.4 Global Targeted SSTR Radionuclide Drug Conjugates Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Targeted SSTR Radionuclide Drug Conjugates Revenue (2021-2032)
  8. 7.2.2 North America Targeted SSTR Radionuclide Drug Conjugates Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Targeted SSTR Radionuclide Drug Conjugates Revenue (2021-2032)
  11. 7.3.2 Europe Targeted SSTR Radionuclide Drug Conjugates Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Targeted SSTR Radionuclide Drug Conjugates Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Targeted SSTR Radionuclide Drug Conjugates Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Targeted SSTR Radionuclide Drug Conjugates Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Targeted SSTR Radionuclide Drug Conjugates Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Curium Pharma
  2. 8.1.1 Curium Pharma Company Information
  3. 8.1.2 Curium Pharma Business Overview
  4. 8.1.3 Curium Pharma Targeted SSTR Radionuclide Drug Conjugates Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Curium Pharma Targeted SSTR Radionuclide Drug Conjugates Product Portfolio
  6. 8.1.5 Curium Pharma Recent Developments
  7. 8.2 ITM Radiopharma
  8. 8.2.1 ITM Radiopharma Company Information
  9. 8.2.2 ITM Radiopharma Business Overview
  10. 8.2.3 ITM Radiopharma Targeted SSTR Radionuclide Drug Conjugates Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 ITM Radiopharma Targeted SSTR Radionuclide Drug Conjugates Product Portfolio
  12. 8.2.5 ITM Radiopharma Recent Developments
  13. 8.3 RadioMedix
  14. 8.3.1 RadioMedix Company Information
  15. 8.3.2 RadioMedix Business Overview
  16. 8.3.3 RadioMedix Targeted SSTR Radionuclide Drug Conjugates Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 RadioMedix Targeted SSTR Radionuclide Drug Conjugates Product Portfolio
  18. 8.3.5 RadioMedix Recent Developments
  19. 8.4 Novartis
  20. 8.4.1 Novartis Company Information
  21. 8.4.2 Novartis Business Overview
  22. 8.4.3 Novartis Targeted SSTR Radionuclide Drug Conjugates Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Novartis Targeted SSTR Radionuclide Drug Conjugates Product Portfolio
  24. 8.4.5 Novartis Recent Developments
  25. 8.5 Grand Pharmaceutical
  26. 8.5.1 Grand Pharmaceutical Company Information
  27. 8.5.2 Grand Pharmaceutical Business Overview
  28. 8.5.3 Grand Pharmaceutical Targeted SSTR Radionuclide Drug Conjugates Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Grand Pharmaceutical Targeted SSTR Radionuclide Drug Conjugates Product Portfolio
  30. 8.5.5 Grand Pharmaceutical Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Targeted SSTR Radionuclide Drug Conjugates Value Chain Analysis
  2. 9.1.1 Targeted SSTR Radionuclide Drug Conjugates Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Targeted SSTR Radionuclide Drug Conjugates Production Mode & Process
  6. 9.2 Targeted SSTR Radionuclide Drug Conjugates Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Targeted SSTR Radionuclide Drug Conjugates Distributors
  9. 9.2.3 Targeted SSTR Radionuclide Drug Conjugates Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst